valbenazine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
0102020152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVE Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics… (More)
Is this relevant?
2017
2017
n engl j med 376;26 nejm.org June 29, 2017 are already prohibited) — a provision that, if included in a Senate bill, would cause… (More)
Is this relevant?
2017
2017
The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed… (More)
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Tardive dyskinesia (TD) is a hyperkinetic movement disorder that may result from treatment with antipsychotics or… (More)
Is this relevant?
Review
2017
Review
2017
Tardive dyskinesia (TD) remains a clinical concern for any patient who receives an antipsychotic. While the overall risk of… (More)
Is this relevant?
2017
2017
  • Kate Traynor
  • American journal of health-system pharmacy : AJHP…
  • 2017
628 AM J HEALTH-SYST PHARM | VOLUME 74 | NUMBER 10 | MAY 15, 2017 FDA in October 2016 announced that PharmaTech’s water system… (More)
Is this relevant?
2017
2017
BACKGROUND Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive… (More)
Is this relevant?
Review
2016
Review
2016
Valbenazine (NBI-98854, Ingrezza) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates… (More)
Is this relevant?
2015
2015
The chronic use and high dosing of typical neuroleptics or centrally acting dopamine receptor blocking antiemetics predispose… (More)
  • figure 1
Is this relevant?